Zai Lab logo

Zai Lab Share Price (NASDAQ: ZLAB)

$33.06

0.84

(2.61%)

Last updated on

Check the interactive Zai Lab Stock chart to analyse performance

Zai Lab stock performance

as on August 30, 2025 at 1:29 am IST

  • Today's Low:$32.88
    Today's High:$33.47

    Day's Volatility :1.78%

  • 52 Weeks Low:$18.91
    52 Weeks High:$44.34

    52 Weeks Volatility :57.35%

Zai Lab Stock Returns

PeriodZai Lab LtdSector (Health Care)Index (Russel 2000)
3 Months
6.16%
3.6%
0.0%
6 Months
4.35%
-7.7%
0.0%
1 Year
71.11%
-12.6%
0.0%
3 Years
-28.47%
9.5%
-4.7%

Zai Lab Ltd Key Stats

Check Zai Lab key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$32.22
Open
$32.985
Today's High
$33.47
Today's Low
$32.875
Market Capitalization
$3.6B
Today's Volume
$378.3K
52 Week High
$44.34
52 Week Low
$18.91
Revenue TTM
$427.8M
EBITDA
$-233.9M
Earnings Per Share (EPS)
$-2.0
Profit Margin
-49.68%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-28.41%

Stock Returns calculator for Zai Lab Stock including INR - Dollar returns

The Zai Lab stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Zai Lab investment value today

Current value as on today

₹1,76,137

Returns

₹76,137

(+76.14%)

Returns from Zai Lab Stock

₹70,853 (+70.85%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Zai Lab Stock

-15%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Zai Lab Stock from India on INDmoney has decreased by -15% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Zai Lab Ltd

  • Name

    Holdings %

  • FMR Inc

    5.80%

  • Capital World Investors

    5.49%

  • RTW INVESTMENTS, LLC

    5.04%

  • ClearBridge Advisors, LLC

    2.98%

  • Morgan Stanley - Brokerage Accounts

    2.40%

  • HHG PLC

    2.00%

Analyst Recommendation on Zai Lab Stock

Rating
Trend

Buy

    83%Buy

    16%Hold

    0%Sell

Based on 12 Wall street analysts offering stock ratings for Zai Lab(by analysts ranked 0 to 5 stars)

Zai Lab Share Price Target

What analysts predicted

Upside of 70.34%

Target:

$56.31

Current:

$33.06

Zai Lab share price target is $56.31, a slight Upside of 70.34% compared to current price of $33.06 as per analysts' prediction.

Zai Lab Stock Insights

  • Price Movement

    In the last 7 days, ZLAB stock has moved down by -5.5%
  • Increasing Revenue

    Revenue is up for the last 2 quarters, 106.48M → 109.97M (in $), with an average increase of 3.2% per quarter
  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -81.68M → -40.72M (in $), with an average increase of 43.8% per quarter
  • ZLAB vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 3.9%
  • ZLAB vs ALNY (3 yr)

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.6% return, outperforming this stock by 136.2%
  • Price to Sales

    ForZLAB every $1 of sales, investors are willing to pay $8.1, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Zai Lab Ltd Financials

Revenue
Profit
Cash Flow
Annually
Quarterly
FY19
FY20
FY21
FY22
FY23
FY24
FY24Y/Y Change
Revenue
$399.0M
↑ 49.59%
Net Income
$-257.1M
↓ 23.17%
Net Profit Margin
-64.44%
↑ 61.02%

Zai Lab Technicals Summary

Sell

Neutral

Buy

Zai Lab is currently in a neutral trading position according to technical analysis indicators.

Zai Lab Ltd Vs Peers

Returns
Ratio's
Overview
Company Name1 Month6 Month1 Year3 Years5 Years
Zai Lab Ltd logo
-12.41%
4.35%
71.11%
-28.47%
-59.15%
Regeneron Pharmaceuticals, Inc. logo
6.48%
-15.2%
-50.31%
-3.3%
-2.01%
Beone Medicines Ltd logo
1.77%
24.81%
62.78%
79.11%
29.69%
Vertex Pharmaceuticals Incorporated logo
-14.45%
-19.13%
-17.84%
34.68%
41.87%
Alnylam Pharmaceuticals, Inc. logo
13.79%
83.28%
75.87%
111.28%
242.25%

About Zai Lab Ltd

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company's oncology pipeline includes bemarituzumab, tumor treating fields, tisotumab vedotin, and repotrectinib; and immunology, neuroscience, and infectious disease pipeline comprises efgartigimod and xanomeline and trospium chloride. Zai Lab Limited has license and collaboration agreements with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure Ltd. to develop and commercialize Tumor Treating Fields; Deciphera Pharmaceuticals, LLC to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx BV to develop and commercialize efgartigimod; Bristol-Myers Squibb Company to develop and commercialize tisotumab vedotin and repotrectinib; Amgen Inc. to develop and commercialize bemarituzumab; Innoviva, Inc. to develop and commercialize Sulbactam-Durlobactam; and Karuna Therapeutics, Inc. to develop and commercialize Xanomeline and trospium chloride, as well as strategic collaboration with Pfizer Inc. for sulbactam and durlobactam. The company was incorporated in 2013 and is headquartered in Pudong, China.
Organization
Zai Lab
Employees
1869
CEO
Dr. Ying Du Ph.D.
Industry
Health Technology

Key Management of Zai Lab Ltd

NameTitle
Dr. Ying Du Ph.D.
Founder, Chairperson & CEO
Mr. Joshua L. Smiley
President & COO
Dr. Rafael G. Amado M.D.
President and Head of Global Research & Development
Dr. Yajing Chen Ph.D.
Chief Financial Officer
Mr. Frazor Titus Edmondson III, J.D.
Chief Legal Officer & Corporate Secretary
Ms. Christine Chiou
Senior VP & Head of Investor Relations
Dr. Jonathan J. Wang MBA, Ph.D.
Chief Business Officer
Dr. James Yan DABT, M.D., Ph.D.
Chief Operating Officer of R&D
Mr. Tong Zhu
Chief Commercial Officer of Greater China

Important FAQs about investing in ZLAB Stock from India :

What is Zai Lab share price today?

Zai Lab share price today is $33.06 as on at the close of the market. Zai Lab share today touched a day high of $33.47 and a low of $32.88.

What is the 52 week high and 52 week low for Zai Lab share?

Zai Lab share touched a 52 week high of $44.34 and a 52 week low of $18.91. Zai Lab stock price today i.e. is closed at $33.06, lower by 25.44% versus the 52 week high.

How to invest in Zai Lab Stock (ZLAB) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Zai Lab on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Zai Lab Shares that will get you 0.0454 shares as per Zai Lab share price of $33.06 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Zai Lab Stock (ZLAB) from India?

Indian investors can start investing in Zai Lab (ZLAB) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Zai Lab stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Zai Lab share’s latest price of $33.06 as on August 30, 2025 at 1:29 am IST, you will get 0.3025 shares of Zai Lab. Learn more about fractional shares .

What are the returns that Zai Lab has given to Indian investors in the last 5 years?

Zai Lab stock has given -59.15% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?